Forum Topic News
  • Conversation: US OKs Sanofi, Regeneron’s new skin cancer immunotherapy

    • October 1, 2018 2:35 PM BST
      • Post(s)

      US OKs Sanofi, Regeneron’s new skin cancer immunotherapy

      Sanofi and Regeneron’s imunotherapy Libtayo has been cleared in the US to treat patients with certain forms of cutaneous squamous cell carcinoma (CSCC).
      The decision, which follows a priority review, allows physicians to prescribe the drug to patients with metastatic CSCC or for those with locally advanced CSCC who are not candidates for curative surgery or radiation.
      Advanced CSCC is the deadliest non-melanoma skin cancer, responsible for around 7,000 deaths in the US each year. There are currently no FDA-approved treatments for the condition.
      Libtayo (cemiplimab) is an investigational human monoclonal antibody that targets the checkpoint inhibitor PD-1, and was granted Breakthrough Therapy designation status in the US last year.
      Read more:,_regenerons_new_skin_cancer_immunotherapy_1254056

Add Reputation

Do you want to add reputation for this member by this post?

or cancel